One company that has been gaining acclaim in their industry, but not on Wall Street, is NanoViricides. An odd series of events is causing confusion in the marketplace.

NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. Based in Connecticut, the young company has gained raved reviews for its HIVCode which could result in a functional cure for HIV/AIDS. Besides the HIVCode, NanoViricides has been making progress in all aspects of their company.

NanoViricides has reported that it is well-financed into the future and its game changing anti-viral and drug programs have continued to develop successfully. Recently, Nano announced that is raised $4.3 million in equity financing which should be sufficient for 18 months or beyond December 2010.

Leading the way at Nano is Dr. Eugene Seymour who serves as their CEO. Dr. Seymour is a renowned name in the industry

Hana Biosciences is a company that is clearly moving in the right direction. The company’s lead product candidate, Marquibo, has been developed to help all cancer patients battle the deadly disease and with news released today, the concept has a great deal of backing.

The young California Company announced there is a definite agreement in place with accredited investors to sell units consisting of common stocks and warrants which will result in total cash proceeds of $12.4 million the closing of which is expected to occur prior to October 9th with Piper Jaffray and Co. serving as exclusive place agent for the transaction.

The net proceeds of this offering will be used to support the completion of the pivotal Phase 2 clinical trial of Marquibo in adult patients with Philadelphia Chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment. The

If there is one disease that has plagued our country and people across the globe, it would be cancer. Perhaps there is not a more tragic situation than when a child is stricken down with the deadly disease. One company is trying to make headway into Pediatric Cancer. That company is Hana Biosciences.

The San Francisco based Hana Biosciences is a biopharmaceutical company that has dedicated their resources and time to developing and commercializing new and differentiated cancer therapies with a plan to improve and enable standards of care amongst cancer patients. Hana took a major step towards achieving this goal with the announcement that they have entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marquibo which is a vincristine sulfate liposomes injection in refractory pediatric cancer.

The CTA will occur over five-years